hERG1 behaves as biomarker of progression to adenocarcinoma in Barrett's esophagus and can be exploited for a novel endoscopic surveillance

Barrett's esophagus (BE) is the only well-known precursor lesion of esophageal adenocarcinoma (EA). The exact estimates of the annual progression rate from BE to EA vary from 0.07% to 3.6%. The identification of BE patients at higher risk to progress to EA is hence mandatory, although difficult...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Oncotarget
Main Authors: Lastraioli, Elena, Lottini, Tiziano, Iorio, Jessica, Freschi, Giancarlo, Fazi, Marilena, Duranti, Claudia, Carraresi, Laura, Messerini, Luca, Taddei, Antonio, Ringressi, Maria Novella, Salemme, Marianna, Villanacci, Vincenzo, Vindigni, Carla, Tomezzoli, Anna, Mendola, Roberta La, Bencivenga, Maria, Compagnoni, Bruno, Chiudinelli, Mariella, Saragoni, Luca, Manzi, Ilaria, Manzoni, Giovanni De, Bechi, Paolo, Boni, Luca, Arcangeli, Annarosa
פורמט: Artigo
שפה:Inglês
יצא לאור: Impact Journals LLC 2016
נושאים:
Research Paper
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5312329/
https://ncbi.nlm.nih.gov/pubmed/27517748
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.11149
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים